Apr 15, 2008, 2008 -
Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that preclinical data from a model of small cell lung cancer (SCLC) show that following treatment with chemotherapy, once-daily oral administration of IPI-926 leads to a statistically significant delay in tumor re-growth, compared to vehicle control (p=0.01). These results suggest that inhibiting the Hedgehog pathway with IPI-926, Infinity's novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in SCLC. These data were presented today during the Annual Meeting of the
American Association of Cancer Research (AACR) in San Diego, California...
Infinity Pharmaceuticals' Press Release -
April 15, 2008 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MedImmune announced that preclinical studies evaluating lead drug candidate retaspimycin hydrochloride ("retaspimycin," also known as IPI-504) suggest that retaspimycin represents a novel strategy for the potential treatment of patients with non-small cell lung cancer (NSCLC) who exhibit resistance to Iressa® (gefitinib) or Tarceva® (erlotinib). 
Data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California. Retaspimycin, a selective small molecule inhibitor of heat shock protein 90 (Hsp90), is currently being evaluated in the Phase 2 portion of an ongoing Phase 1/2 clinical trial in patients with advanced non-small cell lung cancer... MedImmune's Press Release - Infinity's Press Release -
